On the whole, this study unmasked that SNHG14 aggravates CRC progression through inhibiting EPHA7 by upregulating EZH2 via recruiting FUS and absorbing miR-186-5p (Fig. 7), suggesting a new road for CRC diagnosis and treatment. This evidence concerns the gene EZH2 and colorectal carcinoma.